📇 Rhumatologue · BOIS GUILLAUME · (76) · Libéral

M CHRISTOPHE THOMAS

Pourquoi vous devez consulter ce praticien

5 raisons identifiées

Auteur de référence en rhumatologie
21 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (1 thèse dirigée)
Cabinet de groupe — continuité de soins
Plusieurs praticiens dans le même cabinet — un confrère peut prendre le relais en cas d'absence
Disponibilité géographique
7 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
119.2 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 BOIS GUILLAUME (76)LibéralRPPS 10001962140

📊 Reconnaissance scientifique : 16/100📝 77 articles publiés🇫🇷 Publications académiques françaises (8)🎓 1 thèse dirigée

✨ Génération du profil synthétique IA en cours…

Direction de thèses

🎓 1 thèse dirigée

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2023

📚 148 citations🎯 RCR 26.06Top 0% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Impact of age at diagnosis, sex, and immunopathological manifestations in 886 patients with pediatric chronic immune thrombocytopenia

American journal of hematology · 2023

📚 14 citations🎯 RCR 2.50Top 20% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

AbstractPediatric chronic immune thrombocytopenia (cITP) is a heterogeneous condition in terms of bleeding severity, second‐line treatment use, association with clinical and/or biological immunopathological manifestations (IMs), and progression to systemic lupus erythematosus (SLE). No risk factors for these outcomes are known. Specifically, whether age at ITP diagnosis, sex, or IMs impact cITP outcomes is unknown. We report the outcomes of patients with pediatric cITP from the French nationwide prospective cohort OBS'CEREVANCE. We used multivariate analyses to investigate the effect of age at ITP diagnosis, sex, and IMs on cITP outcomes. We included 886 patients with a median (min‐max) follow‐up duration of 5.3 (1.0–29.3) years. We identified an age cutoff that dichotomized the risk of the outcomes and defined two risk groups: patients with ITP diagnosed <10 years (children) and ≥ 10 years (adolescents). Adolescents had a two to four‐fold higher risk of grade ≥3 bleeding, second‐line treatment use, clinical and biological IMs, and SLE diagnosis. Moreover, female sex and biological IMs were independently associated with higher risks of biological IMs and SLE diagnosis, second‐line treatment use, and SLE diagnosis, respectively. The combination of these three risk factors defined outcome‐specific risk groups. Finally, we showed that patients clustered in mild and severe phenotypes, more frequent in children and adolescents, respectively. In conclusion, we identified that age at ITP diagnosis, sex, and biological IMs impacted the long‐term outcomes of pediatric cITP. We defined risk groups for each outcome, which will help clinical management and further studies.

How do study design features and participant characteristics influence willingness to participate in clinical trials? Results from a choice experiment

BMC medical research methodology · 2022

📚 11 citations🎯 RCR 1.16🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Background Research about the decision to participate in a clinical study has tended to be limited to single indications and has focused on narrow sets of study and participant characteristics. This study applied stated preference methods to understand the clinical trial design attributes that most influence willingness to participate and how this varied with participant characteristics. Methods Adults residing in the US, China, or Poland with a self-reported diagnosis of cancer, heart disease, migraine, rheumatoid arthritis, or multiple sclerosis completed an online survey. Participants were asked whether they would participate in clinical studies defined by seventeen attributes within five categories (payment/support, administration/procedures, treatment-related, study location/time commitment, and data collection/feedback). Participants saw six different hypothetical clinical study profiles. Depending on their participation decision to an initial clinical study profile, the subsequent five questions had one design attribute (randomly selected per question) consecutively improved or deteriorated to elicit preferences. A logistic regression was used to determine which participant characteristics influenced participation decisions. A latent class logit model was used to identify how the influence of study design features varied between participants and whether groups of participants with similar preferences could be identified. Results The survey was completed by 487 participants (32% China, 35% Poland, 33% US; 8%–19% per indication). Willingness to participate was found to be a function of participant age, certain elements of quality of life, and previous treatment experience, in particular number of lines of treatment received and experience of adverse events. Willingness to participate was influenced by study design features such as payment, study duration, and time commitment – both the overall time and whether the time was at home or away from home, with the latter being particularly relevant to participants experiencing fatigue due to their disease. Conclusions This study quantifies how study designs influence willingness to participate and how this varies with participant types. These findings suggest that it is how an indication influences quality of life and treatment experience, rather than the indication alone, that impacts participation rates, opening the way for insights that are transferrable across indications, which may be particularly useful when considering rare diseases.

Cookies & analyse de trafic

M CHRISTOPHE THOMAS

Pourquoi vous devez consulter ce praticien

Direction de thèses

Activité de recherche & publications

Publications académiques en France

Lieux de consultation(7)

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (21) — classées par pathologie

Transversal6

Pédiatrie4

Case report / série3

Revue générale3

Épidémiologie & registres2

csDMARDs1

Génétique1

Lupus1

Pharmacovigilance1

Recommandations1

Revue / méta-analyse1

Vraie vie / RWE1

Datasets & protocoles partagés

Partager cette fiche